These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 27999883)

  • 1. The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus.
    Dudkowski C; Tsai M; Liu J; Zhao Z; Schmidt E; Xie J
    Eur J Clin Pharmacol; 2017 Mar; 73(3):279-288. PubMed ID: 27999883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.
    Christopher R; Covington P; Davenport M; Fleck P; Mekki QA; Wann ER; Karim A
    Clin Ther; 2008 Mar; 30(3):513-27. PubMed ID: 18405789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus.
    Ndefo UA; Okoli O; Erowele G
    Am J Health Syst Pharm; 2014 Jan; 71(2):103-9. PubMed ID: 24375601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus.
    Chen XW; He ZX; Zhou ZW; Yang T; Zhang X; Yang YX; Duan W; Zhou SF
    Clin Exp Pharmacol Physiol; 2015 Dec; 42(12):1225-38. PubMed ID: 26218204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.
    Deacon CF
    Curr Opin Investig Drugs; 2008 Apr; 9(4):402-13. PubMed ID: 18393107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.
    Covington P; Christopher R; Davenport M; Fleck P; Mekki QA; Wann ER; Karim A
    Clin Ther; 2008 Mar; 30(3):499-512. PubMed ID: 18405788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus.
    Jarvis CI; Cabrera A; Charron D
    Ann Pharmacother; 2013 Nov; 47(11):1532-9. PubMed ID: 24285765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alogliptin for the treatment of type 2 diabetes.
    White JR
    Drugs Today (Barc); 2011 Feb; 47(2):99-107. PubMed ID: 21431099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin.
    Capuano A; Sportiello L; Maiorino MI; Rossi F; Giugliano D; Esposito K
    Drug Des Devel Ther; 2013; 7():989-1001. PubMed ID: 24068868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alogliptin benzoate for the treatment of type 2 diabetes.
    Rendell M; Drincic A; Andukuri R
    Expert Opin Pharmacother; 2012 Mar; 13(4):553-63. PubMed ID: 22296609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alogliptin benzoate for management of type 2 diabetes.
    Saisho Y
    Vasc Health Risk Manag; 2015; 11():229-43. PubMed ID: 25914541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation.
    Yabe D; Seino Y
    Expert Opin Drug Saf; 2016; 15(2):249-64. PubMed ID: 26607297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects.
    Karim A; Covington P; Christopher R; Davenport M; Fleck P; Li X; Wann E; Mekki Q
    Int J Clin Pharmacol Ther; 2010 Jan; 48(1):46-58. PubMed ID: 20040339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alogliptin: a review of its use in the management of type 2 diabetes mellitus.
    Scott LJ
    Drugs; 2010 Oct; 70(15):2051-72. PubMed ID: 20883057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alogliptin: safety, efficacy, and clinical implications.
    Marino AB; Cole SW
    J Pharm Pract; 2015 Feb; 28(1):99-106. PubMed ID: 24532820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alogliptin (nesina) for type 2 diabetes.
    Med Lett Drugs Ther; 2013 May; 55(1417):41-3. PubMed ID: 23715128
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.
    Lee B; Shi L; Kassel DB; Asakawa T; Takeuchi K; Christopher RJ
    Eur J Pharmacol; 2008 Jul; 589(1-3):306-14. PubMed ID: 18538760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alogliptin; a review of a new dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of type 2 diabetes mellitus.
    Said S; Nwosu AC; Mukherjee D; Hernandez GT
    Cardiovasc Hematol Disord Drug Targets; 2014; 14(1):64-70. PubMed ID: 24993124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis.
    Fujii Y; Abe M; Higuchi T; Mizuno M; Suzuki H; Matsumoto S; Ito M; Maruyama N; Okada K; Soma M
    Expert Opin Pharmacother; 2013 Feb; 14(3):259-67. PubMed ID: 23289982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.